Literature DB >> 33337800

Defining a Therapeutic Window for Rituximab Maintenance Therapy in ANCA-Associated Vasculitis: A Longitudinal Observational Study.

Jason Michael Springer1, Ryan S Funk2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33337800      PMCID： PMC8203744          DOI： 10.1097/RHU.0000000000001688

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN： 1076-1608            Impact factor:   3.902


× No keyword cloud information.
  7 in total

1.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  The Influence of Different Disease States on Rituximab Pharmacokinetics.

Authors:  Xiaoxing Wang; Wenwen Du; Xianglin Zhang; Pengmei Li
Journal:  Curr Drug Metab       Date:  2020       Impact factor: 3.731

3.  Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.

Authors:  Pierre Charles; Élodie Perrodeau; Maxime Samson; Bernard Bonnotte; Antoine Néel; Christian Agard; Antoine Huart; Alexandre Karras; François Lifermann; Pascal Godmer; Pascal Cohen; Catherine Hanrotel-Saliou; Nicolas Martin-Silva; Grégory Pugnet; François Maurier; Jean Sibilia; Pierre-Louis Carron; Pierre Gobert; Nadine Meaux-Ruault; Thomas Le Gallou; Stéphane Vinzio; Jean-François Viallard; Eric Hachulla; Christine Vinter; Xavier Puéchal; Benjamin Terrier; Philippe Ravaud; Luc Mouthon; Loïc Guillevin
Journal:  Ann Intern Med       Date:  2020-06-02       Impact factor: 25.391

4.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

5.  Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited.

Authors:  Amina Bensalem; Denis Mulleman; Gilles Paintaud; Nicolas Azzopardi; Valérie Gouilleux-Gruart; Divi Cornec; Ulrich Specks; David Ternant
Journal:  Clin Pharmacokinet       Date:  2020-04       Impact factor: 6.447

6.  Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

Authors:  Pierre Charles; Benjamin Terrier; Élodie Perrodeau; Pascal Cohen; Stanislas Faguer; Antoine Huart; Mohamed Hamidou; Christian Agard; Bernard Bonnotte; Maxime Samson; Alexandre Karras; Noémie Jourde-Chiche; François Lifermann; Pierre Gobert; Catherine Hanrotel-Saliou; Pascal Godmer; Nicolas Martin-Silva; Grégory Pugnet; Marie Matignon; Olivier Aumaitre; Jean-François Viallard; François Maurier; Nadine Meaux-Ruault; Sophie Rivière; Jean Sibilia; Xavier Puéchal; Philippe Ravaud; Luc Mouthon; Loïc Guillevin
Journal:  Ann Rheum Dis       Date:  2018-04-25       Impact factor: 19.103

7.  Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.

Authors:  Divi Cornec; Brian F Kabat; John R Mills; Melissa Cheu; Amber M Hummel; Darrell R Schroeder; Matthew D Cascino; Paul Brunetta; David L Murray; Melissa R Snyder; Fernando Fervenza; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; John H Stone; David R Barnidge; Ulrich Specks
Journal:  Rheumatology (Oxford)       Date:  2018-04-01       Impact factor: 7.580
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.